1. Home
  2. EYE vs DFTX Comparison

EYE vs DFTX Comparison

Compare EYE & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

HOLD

Current Price

$18.81

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$42.87

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EYE
DFTX
Founded
1990
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
EYE
DFTX
Price
$18.81
$42.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
$31.22
$38.50
AVG Volume (30 Days)
2.3M
3.9M
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
202.78
N/A
EPS
0.38
N/A
Revenue
$1,987,488,000.00
N/A
Revenue This Year
$5.56
N/A
Revenue Next Year
$6.58
N/A
P/E Ratio
$47.47
N/A
Revenue Growth
9.00
N/A
52 Week Low
$14.75
$14.62
52 Week High
$30.02
$47.01

Technical Indicators

Market Signals
Indicator
EYE
DFTX
Relative Strength Index (RSI) 55.54 81.21
Support Level $14.84 $17.51
Resistance Level $19.18 N/A
Average True Range (ATR) 0.95 2.55
MACD 0.36 2.19
Stochastic Oscillator 87.86 83.85

Price Performance

Historical Comparison
EYE
DFTX

About EYE National Vision Holdings Inc.

National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: